Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Kymera Therapeutics (KYMR) EBT (2019 - 2025)

Historic EBT for Kymera Therapeutics (KYMR) over the last 7 years, with Q3 2025 value amounting to -$92.6 million.

  • Kymera Therapeutics' EBT fell 2830.96% to -$92.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$332.6 million, marking a year-over-year decrease of 6593.79%. This contributed to the annual value of -$261.9 million for FY2024, which is 5802.23% down from last year.
  • Kymera Therapeutics' EBT amounted to -$92.6 million in Q3 2025, which was down 2830.96% from -$84.7 million recorded in Q2 2025.
  • Kymera Therapeutics' 5-year EBT high stood at -$13.2 million for Q1 2021, and its period low was -$92.6 million during Q3 2025.
  • In the last 5 years, Kymera Therapeutics' EBT had a median value of -$44.9 million in 2022 and averaged -$49.6 million.
  • Per our database at Business Quant, Kymera Therapeutics' EBT surged by 4994.96% in 2023 and then tumbled by 31734.15% in 2024.
  • Quarter analysis of 5 years shows Kymera Therapeutics' EBT stood at -$34.0 million in 2021, then decreased by 13.64% to -$38.7 million in 2022, then skyrocketed by 49.95% to -$19.4 million in 2023, then crashed by 317.34% to -$80.8 million in 2024, then decreased by 14.61% to -$92.6 million in 2025.
  • Its EBT was -$92.6 million in Q3 2025, compared to -$84.7 million in Q2 2025 and -$74.5 million in Q1 2025.